Spero Therapeutics (SPRO) Net Cash Flow (2016 - 2026)

Spero Therapeutics (SPRO) has reported Net Cash Flow for 11 consecutive years, with -$5.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Cash Flow rose 69.73% year-over-year to -$5.4 million; the trailing twelve-month figure through Jun 2026 stood at $19.6 million (up 160.56% YoY), and the FY2025 full-year result was -$12.6 million, up 46.15% from the prior year.
• Net Cash Flow retreated to -$5.4 million in Q2 2026 per SPRO's latest filing, from $15.9 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $58.7 million in Q4 2022 and bottomed at -$40.5 million in Q1 2022.
• Historically, Net Cash Flow has averaged -$3.4 million across 5 years, with a median of -$6.9 million in 2025.
• The widest YoY moves for Net Cash Flow: up 21431.27% in 2022, down 395.57% in 2022.
• Over 5 years, Net Cash Flow stood at $58.7 million in 2022, then tumbled by 129.82% to -$17.5 million in 2023, then tumbled by 33.78% to -$23.4 million in 2024, then jumped by 64.31% to -$8.4 million in 2025, then soared by 35.88% to -$5.4 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$5.4 million, $15.9 million, and -$8.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.